share_log

Cantor Fitzgerald Upgrades Pacific Biosciences to Overweight, Lowers Price Target to $11

Cantor Fitzgerald Upgrades Pacific Biosciences to Overweight, Lowers Price Target to $11

坎托·菲茨杰拉德将太平洋生物科学上调至增持,将目标股价下调至11美元
Benzinga ·  2023/10/31 10:37

Cantor Fitzgerald analyst Ross Osborn upgrades Pacific Biosciences (NASDAQ:PACB) from Neutral to Overweight and lowers the price target from $14 to $11.

康托·菲茨杰拉德分析师罗斯·奥斯本将太平洋生物科学公司(纳斯达克:PACB)的评级从中性上调至加码,并将目标价从14美元下调至11美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发